Sangamo Therapeutics shares up 2.31% after-hours following Pfizer's return to hemophilia A gene therapy development.

viernes, 3 de enero de 2025, 4:06 pm ET1 min de lectura
PFE--
SGMO--
Sangamo Therapeutics, Inc. rose 2.31% in after-hours trading. The company announced that Pfizer would be returning after the development and commercialization of their hemophilia A gene therapy candidate, giroctocogene fitelparvovec.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios